Prevalence of Growth Hormone Deficiency Highest in US in 7MM: Study

Published Date : Jul 03, 2017

ALBANY, New York, July 3, 2017 - announces the addition of a report titled “EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026” to its exhaustive repository. This epidemiological projection of growth hormone deficiency (GHD) is backed by data that has been collated from various government sources, disease monitoring databases, studies, and disease definitions across the 7 major markets (7MM), namely France, Italy, the U.K., the U.S., Germany, Spain, and Japan. The 36-page publication studies the prevalence of growth hormone deficiency in these major markets based on the patient’s sex, age, and etiological classification. This helps create a concise yet all inclusive overview of the epidemiology of growth hormone deficiency, giving readers a clear and accurate comparison of the different markets.

According to the National Organization for Rare Disorders (NORD) in the U.S., growth hormone deficiency is characterized by the insufficient secretion of growth hormone from the pituitary gland. This condition may be congenital or may also be acquired later in life, resulting from various conditions such as infection, trauma, tumor growth in the brain, or radiation therapy. Sometimes GHD may result from no diagnosable cause, which is categorized as idiopathic. Some the variable symptoms of growth hormone deficiency are altered body composition, lower energy levels, reduced muscle strength, osteoporosis, and several lipid abnormalities. Injections of recombinant human growth hormone (rHGH) on a daily basis are required for the treatment of growth hormone deficiency.

For Sample Copy, click here:

The report states that the diagnosed cases of GHD across ages and genders in the 7MM is slated to rise from 109,551 in 2016 to reach 112,450 by 2026 at an annual growth rate of 0.26%. With the exception of Japan and Germany, the number of diagnosed prevalent cases of growth hormone deficiency is set to rise in all the markets. In 2016, the 5EU accounted for 40% of the overall cases of diagnosed GHD, while the U.S. alone accounted for an estimated 48% that year. Japan came in third, with a 13% prevalence of growth hormone deficiency.

The market for growth hormone deficiency has been witnessing steady growth owing to a large patient pool and major technological advances. There is a large unexplored market for GHD therapeutics in emerging economies such as China and India, especially with a rise in research and development activities in these countries for the discovery of improved and cost-effective treatment options.

Other factors giving the growth hormone deficiency market a boost include the rising demand for GHD drugs, ongoing technological advancements for the development of these drugs, and rising geriatric population. Heavy investments by leading players is also sure to give this market a boost. On the flip side, high cost of treatment, strict regulatory approval procedures, and adverse effects of synthetic human growth hormones threaten to hamper the growth of the growth hormone deficiency market.

To order report Call Toll Free: 866-997-4948 or send an email on